Inbrija Capsule
Product Images NDC 0259-6142

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Inbrija (NDC 0259-6142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merz Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Inbrija 01)

Chemical structure of levodopa showing its molecular arrangement with a benzene ring bearing two hydroxyl groups, an amino group, and a carboxyl group.*

FDA Label Image

Figure 1 (Inbrija 02)

A line graph depicting least-square mean plus standard error over time post dose (in minutes) comparing Inbrija 84 mg to placebo. The x-axis represents time post dose from 0 to 60 minutes, and the y-axis shows least-square mean values from 0 to -14. Data points for Inbrija are shown in solid squares with a solid line, and placebo data are shown as open circles with a dashed line, illustrating a greater reduction in the measured outcome with Inbrija over time.*

FDA Label Image

Undefined (Inbrija 03)

An instructional illustration of the Inbrija inhalation capsule device showing its components labeled from left to right: Blue Handle, Capsule Chamber, White Mouthpiece with Alignment Arrows, and Blue Cap. The image visually demonstrates the assembly parts of the levodopa 42 mg inhalation capsule device by Merz Pharmaceuticals.*

FDA Label Image

Figure B (Inbrija 04)

Label for Inbrija levodopa inhalation powder capsules, 42 mg per capsule, with a dosage instruction of full dose = 2 capsules. The label indicates prescription only use, marked by Merz Pharmaceuticals, LLC. The NDC 0259-6142 is shown, along with safety warning not to swallow the capsule and use only with the Inbrija inhaler. The label includes barcodes and spaces for expiration and lot number information.*

FDA Label Image

Figure C (Inbrija 05)

Label for Inbrija 42 mg levodopa inhalation powder capsules for oral inhalation only. The label shows two white capsules each marked with 'A2' and '42 mg per capsule.' It specifies the full dose as two capsules. Marketed by Merz Pharmaceuticals, LLC, Raleigh, NC. Includes lot and expiration date placeholders and cautionary instructions for use only with Inbrija inhaler and not to swallow capsules.*

FDA Label Image

Figure D (Inbrija 06)

Illustration showing two identical, white capsule-shaped objects aligned vertically with a plus sign between them, labeled as Fig. D. No additional labeling or text visible.*

FDA Label Image

Undefined (Inbrija 07)

An instructional illustration showing how to tear off individual packages containing two capsules of Inbrija (levodopa) 42 mg per capsule, a respiratory inhalation dosage form. The packaging show individual dose packets labeled with the product name, strength, and labeler Merz Pharmaceuticals, LLC.*

FDA Label Image

Undefined (Inbrija 08)

Partial packaging label of Inbrija 42 mg capsules by Merz Pharmaceuticals, LLC. The image shows a section instructing to check the expiration date, with placeholders for expiration (EXP: MMYYYY) and lot number. The label also includes images of the capsules and Peel tabs on the blister pack.*

FDA Label Image

Undefined (Inbrija 09)

An instructional illustration titled 'Pull Off Cap Fig. G' showing a person removing the blue cap from an Inbrija levodopa inhalation capsule. The image demonstrates holding the capsule with both hands and pulling the cap outward, indicated by a red arrow pointing right.*

FDA Label Image

Undefined (Inbrija 10)

Illustration showing how to twist and pull off the mouthpiece from an Inbrija levodopa inhalation capsule device. A hand is gripping the mouthpiece and another hand holding the inhaler body with an arrow indicating the direction to twist and pull.*

FDA Label Image

Undefined (Inbrija 11)

An instructional illustration showing the removal of one Inbrija 42 mg levodopa respiratory inhalation capsule from its packaging. The image depicts hands peeling back the package to extract a single white capsule, with arrows indicating the peeling and capsule removal directions.*

FDA Label Image

Undefined (Inbrija 12)

An instructional illustration showing how to load one capsule into the chamber of an inhalation device. The image depicts hands holding a capsule above the chamber opening, with an arrow indicating capsule insertion. A close-up inset details the chamber interior.*

FDA Label Image

Undefined (Inbrija 13)

An instructional illustration for Inbrija (levodopa) inhalation capsules, showing the alignment of arrows on the mouthpiece and handle as part of device assembly or usage instructions. The figure highlights hand positioning and alignment markers on the inhaler components.*

FDA Label Image

Undefined (Inbrija 14)

Instructional illustration showing how to use the Inbrija levodopa respiratory capsule inhaler. It depicts hands compressing the mouthpiece once, indicated by a "click" and arrows pointing inward, demonstrating the mechanism to prepare for inhalation.*

FDA Label Image

Undefined (Inbrija 15)

Instructional diagram showing how to release the mouthpiece on an inhalation device. The image depicts a hand holding the device, with arrows indicating the direction to push or pull, accompanied by a checkmark indicating the correct action.*

FDA Label Image

Undefined (Inbrija 16)

Instructional illustration showing a person holding an inhaler device away from their mouth while exhaling. The image emphasizes exhaling away from the inhaler prior to use, with an arrow indicating the direction of breath out. The figure is labeled 'Fig. N' with the instruction 'Hold Inhaler Away And Breathe Out.'*

FDA Label Image

Undefined (Inbrija 17)

Instructional diagram showing a person inhaling powder using a blue and white inhalation device, labeled as 'Breathe In Deeply To Inhale Powder.' The illustration highlights the powder swirling inside the device with the term 'whirl' and depicts airflow entering the mouth and traveling into the respiratory tract.*

FDA Label Image

Undefined (Inbrija 18)

Instructional diagram showing a side profile of a person's face with an adjacent stopwatch graphic indicating to hold breath for 5 seconds before breathing out, labeled ‘Fig. P.’ This image is part of inhalation use instructions for a respiratory drug product.*

FDA Label Image

Undefined (Inbrija 19)

An instructional illustration showing hands demonstrating how to twist and pull off the mouthpiece of an Inbrija inhalation capsule device. The image depicts the device labeled Inbrija with an arrow indicating the twisting motion to remove the mouthpiece cap.*

FDA Label Image

Undefined (Inbrija 20)

An instructional illustration showing an open hand holding a single capsule, labeled 'Remove Used Capsule' with a 'Fig.R' notation, demonstrating the step of removing a used capsule.*

FDA Label Image

Undefined (Inbrija 21)

Instructional diagram showing a person removing a second capsule from blister packaging, with the text advising to repeat earlier steps with the second capsule. The image likely relates to the use or administration of Inbrija inhalation capsules.*

FDA Label Image

Undefined (Inbrija 22)

An instructional illustration showing a hand dropping two used capsules into a trash container labeled 'Household Trash.' The image is titled 'Throw Out Used Capsules' and corresponds to Fig. T, demonstrating proper disposal of used capsules.*

FDA Label Image

Figure U (Inbrija 23)

An instructional illustration demonstrating how to clean the mouthpiece of an inhalation device from the top end. The image shows a hand holding the mouthpiece with a cloth or swab being rotated to clean it, including a close-up view of the mouthpiece openings being cleaned with a cotton swab.*

FDA Label Image

Figure V (Inbrija 23a)

An instructional illustration showing how to clean the mouthpiece of an inhalation device. One hand holds the device upright while the other hand uses a cotton swab to clean the mouthpiece from the bottom end, depicting the cleaning motion with arrows. A close-up inset shows the cotton swab cleaning inside the mouthpiece.*

FDA Label Image

Figure W (Inbrija 24)

An instructional diagram showing how to attach the mouthpiece to the Inbrija inhalation capsule device. It depicts a hand holding the device and another hand fitting the mouthpiece onto it with a red arrow indicating the attachment direction.*

FDA Label Image

Figure X (Inbrija 24a)

An instructional illustration showing the step to attach the cap on an Inbrija levodopa 42 mg respiratory capsule inhaler. The image depicts hands holding the inhaler device with an arrow indicating the direction to slide the cap onto the inhaler.*

FDA Label Image

Figure Y (Inbrija 25)

Illustration showing the proper storage position for the Inbrija inhaler device containing levodopa inhalation powder. The image features the inhaler in a horizontal orientation with the label "Ready For Storage" and a checkmark indicating correct placement.*

FDA Label Image

Principal Display Panel (42 mg Capsule Blister Pack Carton)

Packaging label for Inbrija 42 mg capsules, a levodopa inhalation powder. The label shows the product is for oral inhalation only, with a warning not to swallow the capsules. It includes contents information (60 capsules, 15 blister strips of 4 capsules each, and 1 inhaler) and states the medication is marketed by Merz Pharmaceuticals, LLC. The label also features the NDC 0259-6142-60 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.